• Active cancer treatment: Monitoring tumour activity during chemotherapy, targeted therapy or immunotherapy.
• Post-treatment follow-up: Ongoing assessment for possible disease recurrence after completion of therapy.
• Baseline molecular review: Establishing ctDNA status prior to initiating treatment.
• Clinical concern for progression: New symptoms, imaging findings or rising tumour markers.
• Treatment response assessment: Evaluating whether current therapy is influencing tumour activity.
• Relapse risk monitoring: Individuals in remission requiring structured molecular follow-up.

Overview

Cancertrack™ Monitoring (ctDNA) measures fragments of tumour-derived DNA that circulate in peripheral blood. These genetic signals can reflect ongoing tumour activity and provide insight into molecular changes that occur during treatment or follow-up.

Changes in ctDNA levels or mutation patterns may be observed before clinical progression becomes evident through imaging or symptom development. Monitoring these trends can help support timely review of treatment strategy or follow-up planning.

Results are interpreted alongside tumour subtype, staging, treatment history, imaging findings and biochemical markers. Reviewing molecular data within this wider clinical framework supports informed decisions around surveillance intensity, therapy adjustment and longer-term disease management.

Practical

Specimen

Whole blood 

Container

• 2 ml SST tube (yellow colour cap) 
• 2 x EDTA tubes (purple colour cap) of 10 ml each

Volume

15-20 mL

Patient preparation

Require 5-6 hours fasting prior collection